| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/16/2002 | WO2001089514A3 Pharmaceutical composition comprising a free-radical scavenging sedative agent and a metal ion chelating agent |
| 05/16/2002 | WO2001088533A3 Lipid uptake assays |
| 05/16/2002 | WO2001087335A3 Method for selectively inhibiting ghrelin action |
| 05/16/2002 | WO2001085144A3 Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione |
| 05/16/2002 | WO2001079843A3 Screening method for compounds |
| 05/16/2002 | WO2001076638A3 Compositions for drug delivery |
| 05/16/2002 | WO2001074857A3 Methods and compositions for modulating integrin-mediated cell-cell interactions |
| 05/16/2002 | WO2001074341A3 Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant |
| 05/16/2002 | WO2001070953A3 Identification of modulators of the inteferon gamma signaling pathway and their use in restenosis treatment |
| 05/16/2002 | WO2001045664A3 Use of aromatic polycyclic compounds as activators of ppars-type receptors in a cosmetic or pharmaceutical composition |
| 05/16/2002 | WO2001029255A3 Diagnostic test for cephalic pain |
| 05/16/2002 | WO2001025408A9 Isolated dishevelled associated kinases, polynucleotides encoding the kinases, and methods of use thereof |
| 05/16/2002 | US20020059653 Modulating protein complex formation in cells; obtain sample tissue, incubate with acetylcholine esterase, expose to modulator, monitor sample for complex formation |
| 05/16/2002 | US20020058817 For cancer therapy |
| 05/16/2002 | US20020058712 Treatment of fibromyalgia with ubiquinone 10 and succinic acid |
| 05/16/2002 | US20020058704 Multicomponent compositions containing chitosan and methods of preparing same |
| 05/16/2002 | US20020058685 Hydantoin derivative compounds, pharmace utical compositions, and methods of using same |
| 05/16/2002 | US20020058682 Administering to a candidate subject in need of such treatment, a thus-effective amount of at least one inhibitor of at least one calcium channel for loosening/slackening and/or relaxing cutaneous and/or subcutaneous human skin |
| 05/16/2002 | US20020058669 Process for the treatment of organophosphate poisoning |
| 05/16/2002 | US20020058656 For the reduction or prevention of dizziness, drowsiness, depression, delirium, lethargy, mania, orthostatic hypotension, restlessness, weakness, and difficulty in being mobile negative side effects caused by agents of pain therapy |
| 05/16/2002 | US20020058649 Administering during follicular phase of female menstrual cycle and in luteal phase, a competitive progesterone antagonist, which is less than an ovulation-inhibiting dose and less than an abortion-inductive dose |
| 05/16/2002 | US20020058648 Useful in estrogen replacement therapy |
| 05/16/2002 | US20020058644 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) |
| 05/16/2002 | US20020058635 Purine L-nucleosides, analogs and uses thereof |
| 05/16/2002 | US20020058618 Method for the treatmennt or prevention of a disease mediated by the alpha-2B-adrenoceptor |
| 05/16/2002 | US20020058616 Coadministration of a an oral bioavailability-enhancing agent (e.g., a cyclosporin F or ketoconazole) with a drug that exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide) |
| 05/16/2002 | US20020058615 Endothelial specific targeting |
| 05/16/2002 | US20020058614 Especially administered by direct injection into the afflicted cartilagenous region or joint. |
| 05/16/2002 | US20020058613 Modulating the expression or bioactivity of a bcl family member in a neural cell such that axonal growth occurs. |
| 05/16/2002 | US20020058611 Therapeutic agent is conjugated to the carrier via a biodegradable disulfide bond. |
| 05/16/2002 | US20020058607 Containing the amino acid sequence (G/S/A/E)-L-F-(F/I/L); each - is a peptide bond, each parenthesis encloses amino acids which are alternatives to one other, and each slash separating the alternative amino acids. |
| 05/16/2002 | US20020058606 Treatment of sexual dysfunction |
| 05/16/2002 | US20020058284 Methods and compositions for treating macrophage-mediated diseases |
| 05/16/2002 | US20020058238 Stop smoking method and composition |
| 05/16/2002 | US20020058073 Compositions and methods for treating neck and shoulder discomfort |
| 05/16/2002 | US20020058072 Use of iodide salt as an aphrodisiac |
| 05/16/2002 | US20020058061 Pharmaceutical dosage form for pulsatile delivery of methylphenidate |
| 05/16/2002 | US20020058050 Treating pain by administering 24 hours opioid formulations exhibiting rapid rise of drug level |
| 05/16/2002 | US20020058036 Novel fibroblast growth factor and nucleic acids encoding same |
| 05/16/2002 | US20020058035 Reducing FSH levels by administering a GnRH antagonist to reduce both plasma FSH and LH levels; treating prostatic intraepithelial neoplasia, pedophilia, infertility, vaginal bleeding; in vitro fertilization and male contraception |
| 05/16/2002 | US20020058034 Treating or ameliorating an autoimmune condition, an allergic reaction or asthma |
| 05/16/2002 | US20020058033 Human anti-epidermal growth factor receptor single-chain antibodies |
| 05/16/2002 | US20020058029 Anti-CD40L, anti-B7.1 (CD80), anti-B7.2(CD86), CD40 antibody or anti-CD4 antibody; both may be administered separately or in combination, and in any order. |
| 05/16/2002 | US20020058022 Novel compounds |
| 05/16/2002 | US20020058013 Bacterial flora-controlling agent; periodontal-pocket bacterial flora-controlling agent that will eliminate or convert the bacteria, fungi, viruses and other microbes into a group of symbiotic bacteria. |
| 05/16/2002 | US20020058010 Foaming cosmetic cream for treating greasy skin and methods for using the same |
| 05/16/2002 | US20020056206 Spray drying process and compositions of fenofibrate |
| 05/16/2002 | DE10056136A1 Inhibiting leukocyte or tumor cell adhesion to vascular endothelial cells e.g. for combating inflammation or metastasis, using e.g. pregnancy proteins or selectin binding liposomes containing calcium-binding compound |
| 05/16/2002 | DE10054294A1 Topische Behandlung bei der Mastalgie Topical treatment of mastalgia |
| 05/16/2002 | DE10053053A1 Pharmazeutische Formulierungen zur Hemmung von entzündlichen Arthritiden Pharmaceutical formulations for inhibition of inflammatory arthritis |
| 05/16/2002 | CA2428492A1 Method for screening agents by modulating the expression of sparc |
| 05/16/2002 | CA2428318A1 Synergistic medicament containing aromatic agents and having an antagonistic, regenerative and/or protagonist decontamination effect |
| 05/16/2002 | CA2428266A1 Substituted alkyldiamines as inhibitors of plasmepsin or related proteases |
| 05/16/2002 | CA2428241A1 Novel human potassium channel beta subunit |
| 05/16/2002 | CA2428179A1 Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides |
| 05/16/2002 | CA2428176A1 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 05/16/2002 | CA2428164A1 Method for the treatment of inflammation |
| 05/16/2002 | CA2428161A1 Substances causing differentiation |
| 05/16/2002 | CA2428159A1 Delayed-release pharmaceutical formulations containing proinsulin c-peptide |
| 05/16/2002 | CA2428141A1 Use of selectin-binding pregnancy proteins, liposomes, native mucin fragments and mimetic compounds for the treatment and prophylaxis of inflammatory diseases, for preventing metastatic spread and for the prophylaxis of tumour diseases |
| 05/16/2002 | CA2427757A1 Therapeutic uses for ip3 receptor-mediated calcium channel modulators |
| 05/16/2002 | CA2427622A1 Methods for detecting the efficacy of anticancer treatments |
| 05/16/2002 | CA2426730A1 Calcilytic compounds |
| 05/16/2002 | CA2426716A1 Acid derivatives useful as serine protease inhibitors |
| 05/16/2002 | CA2426508A1 Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states |
| 05/16/2002 | CA2426049A1 Improved treatment |
| 05/16/2002 | CA2426037A1 A "bach" g protein coupled receptor polypeptide and polynucleotide encoding this receptor |
| 05/16/2002 | CA2426030A1 Methods of treating disorders related to apoe |
| 05/16/2002 | CA2425829A1 Proteases |
| 05/16/2002 | CA2425594A1 Compositions containing hydrolytically unstable compounds |
| 05/15/2002 | EP1205754A2 Method for screening plant extracts for active ingredients |
| 05/15/2002 | EP1205489A1 Polypeptide and nucleic acids encoding the same |
| 05/15/2002 | EP1205218A1 Topical antipsoriaticum comprising urea, a corticoid and a desinfectant |
| 05/15/2002 | EP1205189A2 Combination of a prostaglandin agonist and a HMG-CoA reductase inhibitor for the stimulation of bone growth |
| 05/15/2002 | EP1205183A2 Antimicrobial composition containing cellulose acetate |
| 05/15/2002 | EP1205182A2 Adenosine as antithrombotic |
| 05/15/2002 | EP1204868A1 Cancer treatments and diagnostics utilizing rad51 related molecules and methods |
| 05/15/2002 | EP1204764A2 Methods of screening for angiogenesis modulators |
| 05/15/2002 | EP1204748A2 New g-protein coupled receptor and dna sequences thereof |
| 05/15/2002 | EP1204683A1 Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof |
| 05/15/2002 | EP1204682A2 Compositions and methods for the treatment of tumors |
| 05/15/2002 | EP1204678A1 Moraxella cattarrhalis basb114 antigens and uses thereof |
| 05/15/2002 | EP1204656A2 A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene hydrochloride |
| 05/15/2002 | EP1204426A2 Medical preparation for treating arthrosis, arthritis and other rheumatic joint diseases |
| 05/15/2002 | EP1204423A1 Therapeutic antibody against muc-1 antigen and methods for their use |
| 05/15/2002 | EP1204419A1 Inhibitors of the lectin complement pathway (lcp) and their use |
| 05/15/2002 | EP1204412A2 Use of etodolac to treat cancer |
| 05/15/2002 | EP1204409A1 Microparticles for pulmonary administration |
| 05/15/2002 | EP1204407A2 Implantable active ingredient depot |
| 05/15/2002 | EP1102594B1 Use of sodium chloride to reduce the gastrointestinal toxicity of camptothecin derivatives |
| 05/15/2002 | EP0792163B1 Acne treating-wound healing compositions containing a pyruvate, an antioxidant and a mixture of fatty acids |
| 05/15/2002 | EP0730443B1 Suspension of loteprednol etabonate |
| 05/15/2002 | CN1349423A Composition comprising tramadol aterial and a selective cox-2 inhibitor drug |
| 05/15/2002 | CN1349422A Contraceptive compositions containing cyclic carbramates and amide derivatives |
| 05/15/2002 | CN1349417A Contraceptive compositions containing 3,3-substituted indoline derivatives and use thereof |
| 05/15/2002 | CN1349416A Contraceptive compositions contaiing indoline derivatives and progestational agents |
| 05/15/2002 | CN1349415A Contraceptive compositions contaiing antiprogesting and progestinic |
| 05/15/2002 | CN1349414A Contraceptive compositions containing 2,1-benzisothiazoline 2,2-dioxides and progestations |
| 05/15/2002 | CN1349413A Contraceptive compositions containing quinazolinone and benzoxazine derivatives |
| 05/15/2002 | CN1349412A Contraceptive compositions containing cyclic urea and amide derivatives |